HK Stock Market Move | HENLIUS (02696) rose more than 4% in the afternoon, and Hanbeite was approved to go public in Bolivia. The company is accelerating its expansion in overseas markets.

HENLIUS (02696) rose more than 4% in the afternoon, with an increase of 4.33% to HK$22.9 by the time of publication, with a turnover of HK$38.2759 million. On the news front, the independently developed and produced product Hanbetite (bevacizumab injection) by HENLIUS has officially obtained approval for listing from the National Drug and Health Technology Bureau of Bolivia, marking Hanbetite as the fourth independently developed and produced product by HENLIUS to be approved for listing overseas, following Hanqyou (trastuzumab), H drug Hanshuang (sintilimab), and Hanlikang (rituximab). This approval is based on HENLIUS's exclusive commercial cooperation with Eurofarma, a leading pharmaceutical company in Brazil and Latin America. In addition, HENLIUS announced on February 10th that a Phase 2 clinical study of the injectable HLX43 (targeting PD-L1 antibody - novel DNA topoisomerase I inhibitor conjugate drug) in patients with recurrent or metastatic esophageal squamous cell carcinoma has completed the first dosing in mainland China. The company plans to conduct relevant Phase 2 clinical trials for potential indications including cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancer, once the conditions are met.